May 1, 2008
Submitted by art on Fri, 2008-05-02 07:45.
Teva Pharmaceutical Industries has reported encouraging results from a three-year study evaluating relapsing-remitting multiple sclerosis patients who failed first-line monotherapy and switched treatments.
The results demonstrated that patients who switched from interferon beta (IFN beta) to Copaxone (glatiramer acetate injection) experienced a 77% reduction in annualized relapse rates (0.63 to 0.14). In addition, these patients did not progress significantly in their disability as measured by expanded disability status scale (EDSS).